Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive and R/R CLL After 3-Year FollowUp Yielded High Responsive Durable Rates

452 views
October 18, 2019
Comments 0
Login to view comments. Click here to Login